Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lily G. Bessette"'
Autor:
Deborah J. Wexler, Mehdi Najafzadeh, Ajinkya Pawar, Lily G. Bessette, Anouk Deruaz-Luyet, Patorno E Elisabetta, Sebastian Schneeweiss, Julie M. Paik, Robert J. Glynn, Kimberly G. Brodovicz
Publikováno v:
Diabetes Obes Metab
Objective Over 99% of the EMPA-REG OUTCOME trial participants had established cardiovascular disease (CVD). We aimed to investigate effectiveness and safety outcomes among patients with type 2 diabetes (T2D) initiating empagliflozin vs dipeptidyl pep
Autor:
Luke Zabotka, Sebastian Schneeweiss, Anouk Deruaz-Luyet, Elisabetta Patorno, Lily G. Bessette, Deborah J. Wexler, Lisette Koeneman, Robert J. Glynn, Helen Tesfaye, Mehdi Najafzadeh
Publikováno v:
Diabetes. 70
In the EMPA REG OUTCOME trial, empagliflozin (EMPA) reduced the risk of cardiovascular (CV) death, all-cause mortality, and hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) and established CV disease (CVD). We assessed t
Autor:
Lily G. Bessette, Kristyn Chin, Ajinkya Pawar, Robert J. Glynn, Phyo Htoo, Seoyoung C. Kim, Brendan M. Everett, Elisabetta Patorno, Deborah J. Wexler, Sebastian Schneeweiss
Publikováno v:
Ann Intern Med
Background Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in placebo-controlled trials of patients with type 2 diabetes (T2D) and established cardiov
Autor:
Deborah J. Wexler, Lily G. Bessette, Chintan V. Dave, Medha Munshi, Seoyoung C. Kim, Robert J. Glynn, Sebastian Schneeweiss, Dae Hyun Kim, Elisabetta Patorno, Ajinkya Pawar
Publikováno v:
Diabetes Care
OBJECTIVE Both sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) demonstrated cardiovascular benefits in randomized controlled trials of patients with type 2 diabetes (T2D) generally RESEARCH
Autor:
Anouk Deruaz-Luyet, Mehdi Najafzadeh, Kimberly G. Brodovicz, Elisabetta Patorno, Lily G. Bessette, Martin Kulldorff, Ajinkya Pawar, Steven Sambevski, Sebastian Schneeweiss, Jessica M. Franklin
Publikováno v:
Diabetes. 68
EMPRISE studies the effectiveness, safety and healthcare utilization of empagliflozin (EMPA), a SGLT2 inhibitor, using data from Medicare and 2 U.S. commercial claims datasets (2014-2019). In an analysis on data from 2014-2016, we identified 17,551 p
Autor:
Elisabetta Patorno, Robert J. Glynn, Medha Munshi, Lily G. Bessette, Seoyoung C. Kim, Dae Hyun Kim, Ajinkya Pawar, Sebastian Schneeweiss
Publikováno v:
Diabetes. 68
Both SGLT2i and GLP-1 RA have shown cardiovascular (CV) benefits in RCTs among diabetic patients generally younger than 65 years with CV disease. Whether these agents are associated with differential effectiveness and safety in routine care of older
Autor:
Elisabetta Patorno, Sebastian Schneeweiss, Ajinkya Pawar, Lily G. Bessette, Seoyoung C. Kim, Dae Hyun Kim, Brendan M. Everett, Robert J. Glynn
Publikováno v:
Diabetes. 68
Both SGLT2i inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) have shown cardiovascular (CV) benefits in CV outcome trials among patients with type 2 diabetes (T2D) and established CV disease (CVD). Whether these agents are associated with d